PDCD1 and head and neck squamous cell carcinoma: This latter agent is being used in several clinical trials for HNSCC treatment, either alone or in combination with anti-PD-1 antibodies (clinical trials.gov identifier: NCT03356223, NCT03356587, NCT03292250 NCT04169074, and NCT03356223).